Contribute Try STAT+ Today

Good morning, everyone. Damian Garde here, in for Ed Silverman once more, and with another round of headlines to get your day started.

UK regulators say Bristol-Myers Squibb’s blockbuster cancer drug Opdivo is too expensive for patients with head and neck cancer, PharmaTimes tells us. According to the National Institute for Health and Care Excellence, the nation’s drug pricing watchdog, Opdivo’s cost, about £5,700 (or $7,000) a month, doesn’t justify its effect on quality of life. NICE made a similar ruling on Opdivo’s use in lung cancer last year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.